A woman who used Wegovy and Ozempic says the drugmaker didn't adequately warn her, or other patients, of serious side effects ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S (NYSE:NVO) shared an abstract with data from the company’s next-generation weight loss candidate ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting ...

On Wednesday, Cantor Fitzgerald reaffirmed its positive stance on Novo Nordisk (NYSE:NVO), maintaining an Overweight rating and a price target of $160.00. The reaffirmation came as Novo Nordisk ...